The ApoB100 mouse was developed by MacRae F. Linton et. al. of the Gladstone Institute of Cardiovascular Disease. The model was created by microinjecting the human apolipoprotein B100 gene into C57BL/6J x SJL zygotes. The resultant mice were backcrossed to C57BL/6 for 4 generations (N4). Taconic received stock from Xenogen Biosciences in May 1996. The mice are maintained by backcrossing hemizygous ApoB100 mice with C57BL/6NTac inbred mice.
Wild type for Nnt mutation
Linton MF, Farese RV, Chiesa G, Grass DS, Chin P, Hammer RE, Hobbs HH, Young SG. (1993). Transgenic Mice Expressing High Plasma Concentrations of Human Apolipoproteins B100 and Lipoprotein (a). J Clin Invest, 92: 3029-3037.